Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
7 Mar 22
Current reports
8-K
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
11 Apr 24
8-K
Other Events
18 Mar 24
8-K
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
19 May 23
8-K
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
11 May 23
8-K
Departure of Directors or Certain Officers
16 Mar 23
8-K
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
6 Mar 23
8-K
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
13 Feb 23
8-K
Departure of Directors or Certain Officers
24 Jan 23
8-K
Departure of Directors or Certain Officers
20 Dec 22
Registration and prospectus
S-8
Registration of securities for employees
28 Mar 24
S-8
Registration of securities for employees
6 Mar 23
S-8
Registration of securities for employees
7 Mar 22
S-8
Registration of securities for employees
12 Aug 21
424B4
Prospectus supplement with pricing info
11 Aug 21
S-1MEF
Registration of additional securities for an S-1
9 Aug 21
S-1/A
IPO registration (amended)
9 Aug 21
FWP
Free writing prospectus
9 Aug 21
S-1/A
IPO registration (amended)
9 Aug 21
8-A12B
Registration of securities on exchange
3 Aug 21
Other
EFFECT
Notice of effectiveness
10 Aug 21
CORRESP
Correspondence with SEC
9 Aug 21
CORRESP
Correspondence with SEC
9 Aug 21
CERT
Certification of approval for exchange listing
5 Aug 21
CORRESP
Correspondence with SEC
5 Aug 21
CORRESP
Correspondence with SEC
4 Aug 21
CORRESP
Correspondence with SEC
4 Aug 21
CORRESP
Correspondence with SEC
3 Aug 21
UPLOAD
Letter from SEC
2 Aug 21
CORRESP
Correspondence with SEC
28 Jul 21
Ownership
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
12 Apr 24
4
Valerie Morisset
8 Apr 24
4
Emily Pimblett
20 Mar 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
18 Mar 24
4
Valerie Morisset
4 Mar 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
17 Nov 23
SC 13D/A
AI ETI LLC
13 Nov 23
4
Peter Kolchinsky
22 May 23
4
Simon Tate
22 May 23